Summary
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a new portable low cost vaccine delivery platform for nucleic acid vaccines, commonly used to treat infectious diseases and cancer. Current vaccines are delivered using lipid nanoparticles (LNPs) which are generally considered complex and generally more costly to produce. Furthermore they can exhibit undesirable side effects. These challenges have caused a steady decline in actual adoption despite their demonstrated efficacy. This project aims to develop a new technology to deliver nucl
